Pfizer Stock Price, News & Analysis

Scorpion Therapeutics announced updates for its PI3Kα inhibitor STX-478, including a new collaboration with Pfizer to evaluate a triplet combination therapy for metastatic breast cancer. The collaboration will study STX-478 + atirmociclib + fulvestrant in frontline patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer, with trial initiation planned for 2H25.

Updated Phase 1/2 study results presented at SABCS 2024 showed STX-478 achieved a 23% overall response rate in HR+/HER2- breast cancer and 44% ORR in gynecological tumors. The drug demonstrated favorable safety with minimal dose modifications and no patient discontinuations due to adverse events. The study also revealed a positive dose-response relationship in monotherapy treatment.

Pfizer will present over 100 research abstracts at the American Society of Hematology (ASH) Annual Meeting and San Antonio Breast Cancer Symposium (SABCS) in December. The presentations include data from approved medicines and pipeline candidates for blood and breast cancers, and rare blood disorders.

Key highlights include updated analyses from the ECHELON-3 trial for ADCETRIS in DLBCL, new data for ELREXFIO in multiple myeloma, and nine real-world analyses confirming IBRANCE as a first-line treatment for HR+/HER2- metastatic breast cancer. The company will also present new Phase 1 data for innovative therapies including atirmociclib, vepdegestrant, and PF-07248144.

The presentations span multiple therapeutic areas including hemophilia, with results from the Phase 3 AFFINE gene therapy trial, and sickle cell disease research.

Zai Lab (NASDAQ: ZLAB) and Pfizer announced a strategic collaboration for XACDURO® (sulbactam-durlobactam) in mainland China through November 2028. Pfizer will exclusively handle commercialization activities for XACDURO®, leveraging its anti-infective infrastructure. XACDURO® is the only antimicrobial specifically developed for treating carbapenem-resistant Acinetobacter baumannii (CRAB) in hospital-acquired and ventilator-associated bacterial pneumonia. In China, where Acinetobacter baumannii resistance to carbapenem antibiotics has reached approximately 74%, this collaboration aims to accelerate patient access to this critical therapy.

Pfizer (NYSE: PFE) has appointed Dr. Chris Boshoff as Chief Scientific Officer and President, Research & Development, effective January 1, 2025. Dr. Boshoff, previously Chief Oncology Officer, will oversee all R&D functions across therapeutic areas. During his 11-year tenure at Pfizer, he has delivered 24 approved innovative medicines and biosimilars across 30+ indications.

The company also announced that Roger Dansey will serve as Interim Chief Oncology Officer, while Johanna Bendell will join from Roche as Oncology Chief Development Officer. The Oncology R&D organization will maintain its integrated structure, reporting to Dr. Boshoff.

Pfizer (NYSE: PFE) has received European Commission approval for HYMPAVZI™ (marstacimab), a groundbreaking treatment for severe hemophilia A or B without inhibitors in patients 12 years and older. This marks the first once-weekly subcutaneous treatment approved for severe hemophilia B and the first pre-filled pen/syringe administration option for both types in the EU. The approval is based on Phase 3 study results showing a 35% reduction in annualized bleeding rate compared to routine prophylaxis. HYMPAVZI demonstrated both non-inferiority and superiority to standard treatments, with common side effects including injection site reactions, headache, pruritus, and hypertension.

Pfizer announces a public webcast featuring discussions with Andrew Baum, Chief Strategy and Innovation Officer, and Dave Denton, Chief Financial Officer, at the Jefferies London Healthcare Conference on November 20, 2024, at 9:00 a.m. GMT. The webcast will be accessible through www.pfizer.com/investors, with registration details available immediately. A transcript and replay will be provided within 24 hours and remain accessible for 90 days.

ViiV Healthcare announced 48-week results from the DOLCE study showing that the 2-drug HIV regimen Dovato (dolutegravir/lamivudine) demonstrated comparable efficacy to 3-drug therapy in treating advanced HIV patients. The study involved 230 treatment-naïve individuals with low CD4 counts, with 82% of Dovato patients and 80% of 3-drug therapy patients achieving viral suppression. A post-hoc analysis confirmed Dovato's non-inferiority regardless of baseline viral load. The study population included severely immunosuppressed patients, with 43% having CD4 counts below 100 cells/mL and 69% having high viral loads. Safety profiles were comparable between both treatment groups.

ViiV Healthcare will present 42 abstracts at HIV Glasgow 2024, showcasing data from its HIV treatment and prevention portfolio. Key presentations include analyses of Vocabria + Rekambys (cabotegravir + rilpivirine LA) in over 10,000 people, Dovato in more than 50,000 people, and Apretude in over 1,300 people. The data includes real-world evidence, cost-effectiveness studies, and findings from the DOLCE study exploring the efficacy of two-drug regimen versus three-drug regimen in people with advanced HIV. New findings from the BANNER study on VH3810109, a broadly neutralizing antibody, will also be presented.

Pfizer (NYSE: PFE) has announced a public webcast featuring Aamir Malik, Chief U.S. Commercial Officer and Executive Vice President, at the UBS Global Healthcare Conference on November 13, 2024, at 12:30 p.m. PST.

Investors and the public can access the webcast through www.pfizer.com/investors, where registration details are currently available. A transcript and replay will be accessible within 24 hours after the live discussion and remain available for at least 90 days.